Japan-based Santen Pharmaceuticals’s US subsidiary has invested in Clearside Biomedical, a spin-out launched from research at Emory University and the Georgia Institute of Technology. Clearside, a drug and technology developer for treatment of eye diseases, raised $7.9m from Santen, venture capital firms Mountain Group Capital and Hatteras Venture Partners, Georgia Research Alliance Fund and the…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
